DR study: 25 year results

Article

Although there is a relatively high rate of diabetic retinopathy (DR) progressing to proliferative diabetic retinopathy (PDR), the level of PDR care available has improved, according to 25-year results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), published in the November issue of Ophthalmology.

Although there is a relatively high rate of diabetic retinopathy (DR) progressing to proliferative diabetic retinopathy (PDR), the level of PDR care available has improved, according to 25-year results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), published in the November issue of Ophthalmology.

Ronald Klein, MD, MPH of the Department of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine and Public Health in Madison, US and colleagues conducted the population-based study of diabetic subjects (n=955) living in the Wisconsin area of the US. Participants took insulin, and had been diagnosed with Type 1 diabetes before 30 years of age. Baseline examinations were conducted between 1980 and 1982; follow-up visits were conducted at four, 10, 14 and 25 years, with 520 subjects completing the final follow-up.

At the final follow-up point, the rate of DR improvement was 18%; the cumulative rate of DR progression was 83%, and the rate of progression of DR to PDR was 42%. Overall, factors found to influence (increase) DR progression were: severity of DR (less severe), gender (male), glycosylated haemoglobin level (high or increasing) and diastolic blood pressure (increasing before the four-year follow-up visit). Factors increasing PDR incidence were high body mass index (BMI) at baseline, high systolic blood pressure and glycosylated haemoglobin levels (particularly with an increase before the four year follow-up point), and proteinuria. The more recent the diabetes diagnosis, the lower the prevalence of PDR: this held true independently of the other PDR influential factors.

The researchers concluded that good glycaemic control reduced the risk of DR progression and, although the progression of DR across the study period was high, a more recent diabetes diagnosis decreased the prevalence of PDR, possibly due to an improvement in care over the study period.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.